Guangzhou JEEP Biotechnology (revision 30)
Old revision·03:20, 28 Dec 2024·Hedgerow_Hal
| Guangzhou JEEP Biotechnology Co., Ltd.Organisation | |
|---|---|
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| Legal name | Guangzhou JEEP Biotechnology Co., Ltd. |
| Trading name | JEEP |
| Other designations | JEEP Peptides, JEEP Bio |
| Identity | |
| Founded | Not documented |
| Headquarters | Guangzhou, Guangdong, China |
| Industry | Research-compound supply |
| Shop domain | Visit JEEP |
| Products and documentation | |
| Product scope | research peptides, SARMs and injectable oils |
| Catalogue size | Not documented |
| Documentation | Batch certificate of analysis reported with orders |
| Independent reports | Submitted to this wiki by purchasers; see §Independent testing record |
| Organisation infobox · conventions | |
Guangzhou JEEP Biotechnology Co., Ltd. (trading as JEEP; jeepbio.com) is a research-peptide manufacturer based in Guangzhou, Guangdong, China, trading as JEEP Peptides, with a catalogue concentrated on incretin analogues and a substantial associated third-party testing record.[1][2]
The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]
This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]
Corporate identity and history
[edit]The organisation operates from Guangzhou, in the Pearl River Delta.[1] No incorporation year is documented in sources available to this wiki and none is asserted here.
Its distinguishing feature among the entities covered on this wiki is specialisation: where most catalogues span peptides, SARMs, oils and bulk raw materials in roughly equal measure, this one is weighted heavily towards incretin analogues.[2] A narrower catalogue is not in itself better, but it does mean that the associated report set is concentrated on a small number of analytes, which makes the set more internally comparable than a set spread thinly across a hundred products.[5]
The trading name coincides with a well-known motor-vehicle marque. No relationship exists or is implied, and the coincidence is recorded only because it makes searching for the organisation unusually difficult.
Distribution and dispatch
[edit]The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.
Operations and documentation practice
[edit]Purchaser reports describe lyophilised material in crimped glass vials with a batch certificate, insulated packaging and a cold pack.[5] Certificate content in the submitted set has been comparatively complete for a retail supplier: purity and appearance consistently, water on most lots, and a method statement on some.[6]
The organisation's own material describes direct manufacturing. As with every entity covered here, this wiki cannot distinguish manufacturing from repackaging or brokerage on available sources, and the claim is reproduced as a claim.[2]
Product range
[edit]| Class | Representative listings | Documentation reported |
|---|---|---|
| Incretin analogues | Semaglutide, tirzepatide, retatrutide, cagrilintide | Certificate with purity, water, sometimes method |
| Research peptides | Repair and secretagogue peptides | Certificate, purity and water |
| SARMs and injectable oils | Bulk | Certificate, purity |
The concentration on incretin analogues, including the less commonly listed amylin analogues, is the catalogue's distinguishing feature.[2]
Independent testing record
[edit]The associated report set is substantial and, unusually, concentrated: a large number of reports across a small number of analytes.[5] Reported area percent figures have clustered tightly in the high nineties, with a narrower dispersion than for the broad-catalogue entities.
Narrower dispersion across a concentrated analyte set is a more interpretable observation than a similar figure across a broad one, because fewer of the differences between reports are attributable to different chemistries and different methods.[6] It remains subject to the general limitation: purchaser-submitted, purchaser-selected samples, no documented chain of custody, and therefore no claim about output.[5][7]
See also
References
- ^ a b National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
- ^ a b c d Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
- ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
- ^ PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
- ^ a b c d Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
- ^ a b United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.
- ^ ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories. International Organization for Standardization.